Preclinical Oxygen Imager to Model Efficient Cancer Treatment

摘要 本SBIR第二阶段提案旨在推进SBIR第一阶段项目“Robust”期间取得的进展 小型动物氧气成像仪模拟强化癌症治疗“。在第一阶段，我们开发了一种 健壮氧气成像仪的原型，Jiva-25，用于临床前癌症生物学和放射治疗研究。在……里面 在目前的提案中，我们计划在硬件、软件和图像采集方法方面进行改进 将导致仪器重量减轻，仪器性能更好，以及更高分辨率的氧图。在……里面 此外，我们将通过使用辐射的癌症研究动物实验来评估Jiva-25的性能 治疗和药物应用。 JiVA-25是一台25 Mt氧气成像仪，占地面积小，基于电子顺磁原理 共振氧成像。JiVA-25可提供1 mm空间分辨率、1托的组织氧图 氧气分辨率和1-10分钟的时间分辨率。没有其他与之竞争的方法可以提供准确的 如此精确的非侵入性pO2图。在肿瘤中，准确的实时pO2图将导致氧气引导 放射治疗(OGRT)。OGRT有望通过降低辐射剂量，降低辐射剂量 给氧充足的肿瘤组织的剂量。这将保持受辐射组织的结构和完整性 并减少辐射副作用。缺乏临床前(动物)氧气成像数据是主要原因 阻碍OGRT转化为临床的证据基础的发展。氧气的可得性 临床前环境中的MAP也有望导致先进的药物和放射治疗。提供 使用Jiva-25仪器的研究界是实现这些目标的第一步。

Abstract This SBIR Phase II proposal is designed to advance the progress made during the SBIR Phase I project “Robust Small Animal Oxygen Imager to Model Enhanced Cancer Treatment”. During Phase I, we have developed a prototype of robust oxygen imager, JIVA-25, for preclinical cancer biology and radiation therapy research. In the current proposal, we plan improvements in hardware, software, and image acquisition methodology that will lead to reduced instrument weight, better instrument performance, and higher resolution oxygen maps. In addition, we will evaluate the JIVA-25 performance with cancer research animal studies that use radiation therapy and drug application. JIVA-25 is a 25 mT oxygen imager with small footprint based on the principles of electron paramagnetic resonance oxygen imaging. JIVA-25 can provide oxygen maps in tissues with 1 mm spatial resolution, 1 torr oxygen resolution and 1-10 min temporal resolution. No other competing method can provide accurate noninvasive pO2 maps with such precision. In tumor, accurate real-time pO2 maps will lead to oxygen guided radiation therapy (OGRT). OGRT is expected to reduce the delivered high radiation dose volume by lowering the dose to well-oxygenated tumor tissues. This will preserve the structure and integrity of irradiated tissues and reduce radiation side effects. The absence of preclinical (animal) oxygen imaging data is the major impediment in the development of evidence base for OGRT translation into clinics. The availability of oxygen maps in preclinical settings is also expected to lead to advanced drug and radiation therapies. Providing the research community with JIVA-25 instrument is the first step in achieving these goals.